This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
6 Jul 2012

Medunik Canada & Orphan Europe Ink Deal

Under the distribution agreement, Medunik Canada receives the exclusive Canadian rights to market and distribute four important therapies.

Quebec-based pharmaceutical company Medunik Canada has signed an exclusive distribution agreement with Orphan Europe Recordati Group.

 

Under this agreement, Medunik Canada receives the exclusive Canadian rights to market and distribute four important therapies in the following medical conditions: (1) acute hepatic porphyria, (2) hyperammonaema due to N-acetylglutamate synthase (NAGS) deficiency or one of three organic acidurias (isovaleric, methylmalonic or propionic), (3) patent ductus arteriosus and (4) vitamin E deficiency in chronic cholestasis.

 

"We are thrilled to enter into a new partnership with Orphan Europe Recordati Group" stated éric Gervais, Executive Vice-President of Medunik Canada. "This new strategic collaboration complements our existing alliances

Related News